製品番号: HY-134541

SM-102

50 Cited Publications

カスタマーレビュー

Based on 50 publication(s) in Google Scholar

SM-102 is an amino cationic lipid useful in the formation of lipid nanoparticles (LNPs). SM-102 has higher transfection efficiency. SM-102 plays an important role in the effectiveness of lipid nanoparticles (LNPs) in delivering mRNA therapeutics and vaccines.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.97%
CAS 番号: 2089251-47-6
分子式: C₄₄H₈₇NO₅
分子量:710.17

保管条件:

Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

SM-102 構造式

CAS 番号: 2089251-47-6

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

体外実験

Note: This product is a viscous liquid. To minimize product loss, it is highly recommended to centrifuge the bottle and dissolve the entire contents before aliquoting for storage; please avoid attempting to weigh out the material yourself.

Preparation of Lipid Nanoparticles^[3]^[4]

Here we provide lipid molar ratios for LNPs in FDA-approved mRNA-1273 (a COVID-19 mRNA vaccine). The molar ratio of lipids in this formulation is SM-102 : DSPC : Cholesterol : DMG-PEG 2000 = 50 : 10 : 38.5 : 1.5^[1], and RNA to lipid weight ratio is 0.05 (wt/wt).

A. Lipid Mixture Preparation

1. Dissolve lipids in ethanol and prepare 10 mg/mL stock solutions. The lipid stock solutions can be stored at 20°C for later use.

Note 1: The ionizable lipid is usually a liquid. Due to the viscosity, it should always be weighed rather than relying on the autopipette volume.

Note 2: Cholesterol in solution should be kept warm (>37°C) to maintain fluidity. Transfer the cholesterol solution promptly to avoid cooling.

2. Prepare the lipid mixture solution as described. For each mL of lipid mixture add the following: 572 μL of 10 mg/mL SM-102 (HY-134541), 240 μL of 10 mg/mL Cholesterol (HY-N0322), 127 μL of 10 mg/mL DSPC (HY-W040193), and 61 μL of DMG-PEG 2000 (HY-112764). Mix the solutions thoroμghly to achieve a clear solution. This mixture contains 10 mg of total lipid.

Note 3: The choice of lipids and ratios may be changed as desired and this will affect the LNP properties (size, polydispersity, and efficacy) and the amount of mRNA required.

B. mRNA Preparation

1. Prepare a 166.7 μg/mL mRNA solution with 100 mM pH 5 sodium acetate buffer.

Note 4: The lipid:mRNA weight ratio influences the encapsulation efficiency. Other weight ratios may be prepared as alternative formulations and should be adjusted accordingly by user.

C. Mixing

There are three commonly used methods to achieve rapid mixing of the solutions: the pipette mixing method, the vortex mixing method, and the microfluidic mixing method. All these mixing methods can be used for various applications.

It is important to note that pipette mixing method and vortex mixing method may yield more heterogeneous LNPs with lower encapsulation efficiencies and is prone to variability. Microfluidic devices enable rapid mixing in a highly controllable, reproducible manner that achieves homogeneous LNPs and high encapsulation efficiency. Within these devices, the ethanolic lipid mixture and aqueous solution are rapidly combined in individual streams. LNPs are formed as the two streams mix and are then collected into a single collection tube.

1. Pipette Mixing Method:

1.1. Pipette 3 mL of the mRNA solution and quickly add it into 1 mL of the lipid mixture solution (A 1:3 ratio of ethanolic lipid mixture to aqueous buffer is generally used.) Pipette up and down rapidly for 20-30 seconds.

1.2. Incubate the resulting solution at room temperature for up to 15 minutes.

1.3. After mixing, the LNPs were dialyzed against PBS (pH 7.4) for 2 h, sterile filtered using 0.2 μm filters, and stored at 4°C.

2. Vortex Mixing Method:

1.1. Vortex 3 mL of mRNA solution at a moderate speed on the vortex mixer. Then, Quickly add 1 mL of the lipid mixture solution into the vortexing solution (A 1:3 ratio of ethanolic lipid mixture to aqueous buffer is generally used.). Continue vortexing the resulting dispersion for another 20-30 seconds.

1.2. Incubate the resulting solution at room temperature for up to 15 minutes.

1.3. After mixing, the LNPs were dialyzed against PBS (pH 7.4) for 2 h, sterile filtered using 0.2 μm filters, and stored at 4°C.

3. Microfluidic Mixing Method:

1.1 The 3 mL of mRNA buffer solution and 1 mL of the lipid mixture solution were mixed at a total flow rate of 12 mL/min in a microfluidic device (A 1:3 ratio of ethanolic lipid mixture to aqueous buffer is generally used.).

Note 5: Parameters such as the flow rate ratio and total flow rate can be altered to fine-tune LNPs.

1.2. After mixing, the LNPs were dialyzed against PBS (pH 7.4) for 2 h, sterile filtered using 0.2 μm filters, and stored at 4°C.

Reference

1. Curr Issues Mol Biol. 2022 Oct 19;44(10):5013-5027.

2. Curr Protoc. 2023;3(9):e898.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

化学情報

CAS 番号 2089251-47-6
性状 Liquid (Density: 0.925±0.06 g/cm³)
分子量 710.17
分子式 C₄₄H₈₇NO₅
Color Colorless to light yellow
SMILES

O=C(OC(CCCCCCCC)CCCCCCCC)CCCCCCCN(CCO)CCCCCC(OCCCCCCCCCCC)=O
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (50)

All Cell Proliferation/Viability AssayIn Vivo ImagingOthersFlow CytometryELISA

Sort by:

Journal Impact Factor

Science

Exogenous RNA surveillance by proton-sensing TRIM25. [Abstract]

2025 Apr 4;388(6742):eads4539. PMID: 40179174
Nat Nanotechnol

A disease-severity-responsive nanoparticle enables potent ghrelin messenger RNA therapy in osteoarthritis. [Abstract]

2026 Jan 14. PMID: 41535382
Nat Nanotechnol

Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines. [Abstract]

2023 Sep;18(9):1105-1114. PMID: 37365276
Adv Mater

pH-Responsive β-Glucans-Complexed mRNA in LNPs as an Oral Vaccine for Enhancing Cancer Immunotherapy. [Abstract]

2024 Jun 19:e2404830. PMID: 38895941
Nat Biomed Eng

Optimization of the activity and biodegradability of ionizable lipids for mRNA delivery via directed chemical evolution. [Abstract]

2024 Nov;8(11):1412-1424. PMID: 39578640
Nat Biomed Eng

In vivo affinity maturation of the CD4 domains of an HIV-1-entry inhibitor. [Abstract]

2024 Dec;8(12):1715-1729. PMID: 39638875
Nat Biomed Eng

In vivo affinity maturation of mouse B cells reprogrammed to express human antibodies. [Abstract]

2024 Apr;8(4):361-379. PMID: 38486104
Bioact Mater

β-catenin mRNA encapsulated in SM-102 lipid nanoparticles enhances bone formation in a murine tibia fracture repair model. [Abstract]

2024 May 23:39:273-286. PMID: 38832305
Nat Chem

Fast and facile synthesis of amidine-incorporated degradable lipids for versatile mRNA delivery in vivo. [Abstract]

2024 Oct;16(10):1687-1697. PMID: 38982196

SM-102 purchased from MedChemExpress. Usage Cited in: Nat Chem. 2024 Oct;16(10):1687-1697. [Abstract]

Cytotoxicity of LNPs (SM-102 (or MC3) LNP was formulated by SM-102, DSPC, cholesterol and DMG-PEG at a molar ratio of 50:10:38.5:1.5 using microfluidic mixing). HepG2 cells were treated with the indicated mRNA dose for 24 h. The dashed line indicates 80% cell viability.

SM-102 purchased from MedChemExpress. Usage Cited in: Nat Chem. 2024 Oct;16(10):1687-1697. [Abstract]

Hemolysis test to assess membrane destructive activity(SM-102 (or MC3) LNP was formulated by SM-102, DSPC, cholesterol and DMG-PEG at a molar ratio of 50:10:38.5:1.5 using microfluidic mixing).
ACS Nano

In Situ Tumor-Infiltrating Lymphocyte Therapy by Local Delivery of an mRNA Encoding Membrane-Anchored Anti-CD3 Single-Chain Variable Fragment. [Abstract]

2024 Nov 26;18(47):32401-32420. PMID: 39527145
ACS Nano

Blood Distribution of SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine in Humans. [Abstract]

2024 Oct 1;18(39):27077-27089. PMID: 39298422
Nat Commun

In situ combinatorial synthesis of degradable branched lipidoids for systemic delivery of mRNA therapeutics and gene editors. [Abstract]

2024 Feb 26;15(1):1762. PMID: 38409275
J Biomed Sci

Bivalent mRNA vaccine effectiveness against SARS-CoV-2 variants of concern. [Abstract]

2023 Jun 28;30(1):46. PMID: 37380988
Mol Ther

Targeting vaccine fusion proteins to APCs increases immunogenicity of adenoviral and mRNA-LNP vaccines. [Abstract]

2026 Jun 26:S1525-0016(26)00511-3. PMID: 42363600
Redox Biol

Stromal cell-derived itaconate promotes endometriosis via macrophage NRF2 and lysosomal pH modulation. [Abstract]

2026 May:92:104101. PMID: 41780193
J Control Release

2026 May 22.
J Control Release

Optimized lipid nanoparticles for pulmonary delivery of CRISPR/Cas9 targeting KRAS G12S in lung cancer. [Abstract]

2026 Mar 10:391:114607. PMID: 41506374
J Control Release

Delivery of Itgb1-siRNA by triptolide-modified and anti-Flt1 peptide-guided ionizable cationic LNPs for targeted therapy of corneal neovascularization. [Abstract]

2025 May 3:113811. PMID: 40324532
J Control Release

Impact of pre-existing anti-polyethylene glycol (PEG) IgM on biodistribution and humoral response of intramuscularly administered PEGylated mRNA loaded lipid nanoparticle. [Abstract]

2025 May 6:113821. PMID: 40339658
J Control Release

Physicochemical and structural insights into lyophilized mRNA-LNP from lyoprotectant and buffer screenings. [Abstract]

2024 Aug 2:373:727-737. PMID: 39059500
Small Struct

2026 Mar 6;7(3):e202500583.
J Colloid Interface Sci

The vast majority of nucleic acid-loaded lipid nanoparticles contain cargo. [Abstract]

2024 Jun 23:674:139-144. PMID: 38925059
Adv Healthc Mater

Redirecting Tumor Evolution with Nanocompiler Precision for Enhanced Therapeutic Outcomes. [Abstract]

2024 Jul 23:e2400366. PMID: 39039965
ACS Appl Mater Interfaces

Gastrointestinal Device-Mediated Delivery of mRNA-Lipid Nanoparticles Achieves Distinct Expression and Biodistribution in Mice and Pigs. [Abstract]

2024 Dec 11;16(49):67192-67202. PMID: 39621822
Cell Rep

Exogenous estrogen enhances T cell activation in male primates. [Abstract]

2025 Aug 22;44(9):116170. PMID: 40849906
NPJ Vaccines

mRNA-lipid nanoparticle vaccines provide protection against lethal Nipah virus infection. [Abstract]

2025 Dec 19. PMID: 41419782
Int J Nanomedicine

Optimized Lipid Nanoparticle-Mediated mRNA Co-Delivery of SOX5/SOX9 Enables Synergistic Senescence Reversal for Osteoarthritis Therapy. [Abstract]

2025 Oct 22:20:12783-12804. PMID: 41146650

SM-102 purchased from MedChemExpress. Usage Cited in: Int J Nanomedicine. 2025 Oct 22:20:12783-12804. [Abstract]

Primary chondrocytes were treated with seven different LNP formulations loaded with luciferase mRNA (SM-102 molar ratios ranging from 40% to 60%), and the luminescence intensity was measured 12 hours post‑transfection.
Int J Nanomedicine

Liver-Specific Ionizable Lipid Nanoparticles Mediated Efficient RNA Interference to Clear "Bad Cholesterol". [Abstract]

2023 Dec 19:18:7785-7801. PMID: 38144512
Mol Ther Nucleic Acids

A transferable SARS-CoV-2 IRES module enables dual translation initiation for enhanced antigen expression in COVID-19 mRNA vaccines. [Abstract]

2026 Mar 5;37(2):102886. PMID: 41883582
Pharmaceutics

Unconventional Lysine-Type Lipid Assemblies Enable Efficient Antisense Oligonucleotide Delivery with Distinct Structural Features. [Abstract]

2026 Feb 11;18(2):228. PMID: 41754970
Eur J Pharm Sci

Liposomes and lipid nanoparticles: a tutorial for advanced chemical and structural characterisation. [Abstract]

2026 Jul 1:222:107556. PMID: 42142813
Eur J Pharm Sci

Impact of formulation and process parameters on the stability and bioactivity of RNA-loaded lipid nanoparticles during nebulization. [Abstract]

2026 Jan 1:216:107383. PMID: 41265762
Mol Pharm

Effect of Anti-PEG Antibody on Immune Response of mRNA-Loaded Lipid Nanoparticles. [Abstract]

2024 Nov 4;21(11):5672-5680. PMID: 39324825
Cell Rep Methods

A fluorescent splice-switching mouse model enables high-throughput, sensitive quantification of antisense oligonucleotide delivery and activity. [Abstract]

2024 Jan 22;4(1):100673. PMID: 38171361
Eur J Pharm Biopharm

Interactions between mRNA lipid nanoparticles and immune cells in fresh human whole blood. [Abstract]

2026 Jun 9:115146. PMID: 42264006
Hum Gene Ther

Halting Recombinant Adeno-Associated Virus Transgene Expression Using mRNA-Lipid Nanoparticle-Delivered Meganucleases. [Abstract]

2025 Jun;36(11-12):870-883. PMID: 40356311
J Chromatogr A

A platform method for simultaneous quantification of lipid and nucleic acid components in lipid nanoparticles. [Abstract]

2025 Apr 12:1746:465788. PMID: 39987694
Anal Bioanal Chem

Development of an advanced separation and characterization platform for mRNA and lipid nanoparticles using multi-detector asymmetrical flow field-flow fractionation. [Abstract]

2024 Oct;416(24):5281-5293. PMID: 39102094
Vaccines

Multivalent mRNA Vaccine Elicits Broad Protection against SARS-CoV-2 Variants of Concern. [Abstract]

2024 Jun 26;12(7):714. PMID: 39066352

SM-102 purchased from MedChemExpress. Usage Cited in: Vaccines. 2024 Jun 26;12(7):714. [Abstract]

Summary table shows the molar ratio and physiochemical properties of the mRNA-LNPs (SM-102, DSPC, cholesterol, and DMG-PEG 2000 were mixed in a molar ratio of 50:10:38.5:1.5).

SM-102 purchased from MedChemExpress. Usage Cited in: Vaccines. 2024 Jun 26;12(7):714. [Abstract]

Flow cytometry data showed that each mRNA was successfully transfected and expressed 24 hours later (SM-102, DSPC, cholesterol, and DMG-PEG 2000 were mixed in a molar ratio of 50:10:38.5:1.5).

SM-102 purchased from MedChemExpress. Usage Cited in: Vaccines. 2024 Jun 26;12(7):714. [Abstract]

The binding activity of serum to different strains was detected by ELISA (SM-102, DSPC, cholesterol, and DMG-PEG 2000 were mixed in a molar ratio of 50:10:38.5:1.5).
Electrophoresis

Capillary-Based Physicochemical Characterization of Lipid Nanoparticles. [Abstract]

2025 Sep 28. PMID: 41015920
SSRN

2026 Jun 18.
SSRN

2025 Oct 31.
SSRN

2025 Oct 29.
SSRN

2025 Oct 2.
bioRxiv

2025 Sep 29.
SSRN

2025 May 6.
bioRxiv

Plug-and-play assembly of biodegradable ionizable lipids for potent mRNA delivery and gene editing in vivo. [Abstract]

2025 Mar 1:2025.02.25.640222. PMID: 40060499
bioRxiv

2025 January 21.
bioRxiv

In vivo affinity maturation of the HIV-1 Env-binding domain of CD4. [Abstract]

2024 Feb 5:2024.02.03.578630. PMID: 38370774
Research Square Preprint

2023 Aug 3.

溶剤 & 溶解度

体外:

Ethanol : ≥ 100 mg/mL (140.81 mM)

DMSO : 100 mg/mL (140.81 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.4081 mL

7.0406 mL

14.0811 mL

5 mM

0.2816 mL

1.4081 mL

2.8162 mL

10 mM

0.1408 mL

0.7041 mL

1.4081 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (3.52 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.5 mg/mL.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (3.52 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.5 mg/mL.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.52 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (274 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Escalona-Rayo O, et al. In vitro and in vivo evaluation of clinically-approved ionizable cationic lipids shows divergent results between mRNA transfection and vaccine efficacy. Biomed Pharmacother. 2023 Sep;165:115065. [Content Brief]

[2]. Cho HY, et al. Effective Perturbations on the Amplitude and Hysteresis of Erg-Mediated Potassium Current Caused by 1-Octylnonyl 8-[(2-hydroxyethyl)[6-oxo-6(undecyloxy)hexyl]amino]-octanoate (SM-102), a Cationic Lipid. Biomedicines. 2021 Oct 1;9(10):1367. [Content Brief]

[3]. Mashima R, et al. Lipid Nanoparticles: A Novel Gene Delivery Technique for Clinical Application. Curr Issues Mol Biol. 2022 Oct 19;44(10):5013-5027. [Content Brief]

[4]. McKenzie RE, et al. mRNA Synthesis and Encapsulation in Ionizable Lipid Nanoparticles. Curr Protoc. 2023 Sep;3(9):e898. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	1.4081 mL	7.0406 mL	14.0811 mL	35.2028 mL
	5 mM	0.2816 mL	1.4081 mL	2.8162 mL	7.0406 mL
	10 mM	0.1408 mL	0.7041 mL	1.4081 mL	3.5203 mL
	15 mM	0.0939 mL	0.4694 mL	0.9387 mL	2.3469 mL
	20 mM	0.0704 mL	0.3520 mL	0.7041 mL	1.7601 mL
	25 mM	0.0563 mL	0.2816 mL	0.5632 mL	1.4081 mL
	30 mM	0.0469 mL	0.2347 mL	0.4694 mL	1.1734 mL
	40 mM	0.0352 mL	0.1760 mL	0.3520 mL	0.8801 mL
	50 mM	0.0282 mL	0.1408 mL	0.2816 mL	0.7041 mL
	60 mM	0.0235 mL	0.1173 mL	0.2347 mL	0.5867 mL
	80 mM	0.0176 mL	0.0880 mL	0.1760 mL	0.4400 mL
	100 mM	0.0141 mL	0.0704 mL	0.1408 mL	0.3520 mL

Keywords

SM-102

50 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

SM-102

Anti-Infection Compound Library

Metabolism/Protease Compound Library

Lipid Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Liposome Library

Ionizable Lipid Compound Library

MedChemExpress（MCE）の使用を引用している文献 SM-102

生物活性

化学情報

Publications (50)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

SM-102

Anti-Infection Compound Library

Metabolism/Protease Compound Library

Lipid Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Liposome Library

Ionizable Lipid Compound Library

MedChemExpress（MCE）の使用を引用している文献 SM-102

生物活性

化学情報

Publications (50)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

SM-102 関連分類

HY-134541 関連分類